Barbara Ann Burtness, MD

Professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Director, Developmental Therapeutics Research Program

Physician Biography

Dr. Burtness received her medical degree from the State University of New York at Stony Brook. She completed her internship and residency at Yale-New Haven Hospital, and a fellowship in Hematology/Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Burtness is a member of the American Society for Clinical Oncology and American Association for Cancer Research. She is a member of the editorial board of HemOnc Today, Journal of Clinical Oncology, Frontiers in Oncology, and Clinical Cancer Research. She has authored over 100 peer-reviewed publications.

Clinical Interests

  • Adult
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Yale Cancer Center: Head & Neck Cancers Program

Yale Medicine

Board Certifications

  • Internal Medicine AB of Internal Medicine (1989)

  • Medical Oncology AB of Internal Medicine (1993)

Clinical Trials

Conditions Study Title
Larynx, Lip, Oral Cavity and Pharynx A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Other Skin A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
Larynx, Lip, Oral Cavity and Pharynx A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Phase I An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Lip, Oral Cavity and Pharynx, Soft Tissue A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Larynx, Lip, Oral Cavity and Pharynx Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck
Lip, Oral Cavity and Pharynx A Two-arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
Larynx, Lip, Oral Cavity and Pharynx, Ill-Defined Sites A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Larynx, Lip, Oral Cavity and Pharynx Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lip, Oral Cavity and Pharynx Window Trial 5-aza in HNSCC, T-tare
Lip, Oral Cavity and Pharynx Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Edit this profile

Contact Info

Barbara Ann Burtness, MD
Patient Care Location
Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste NP - 4

New Haven, CT 06511
View on map...
Mailing Address
Medical Oncology25 York Street
PO Box 208028

New Haven, CT 06520-8028